Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms called schistosomes. The urinary tract or the intestines may be infected. Signs and symptoms may include abdominal pain, diarrhea, bloody stool, or blood in the urine. Those who have been infected a long time may experience liver damage, kidney failure, infertility, or bladder cancer. In children, it may cause poor growth and learning difficulty.
Shin Poong, Merck, Bayer, EIPICO, Chandra Bhagat Pharma and Taj Pharmaceuticals are the main manufacturers of drugs for Schistosomiasis.
East Africa is the largest region of drugs for Schistosomiasis, whose market share is about 24%,
Followed by West Africa(20%).
The global Drugs for Schistosomiasis market was valued at US$ 79 million in 2020 and is expected to reach US$ 102.8 million by the end of 2029, growing at a CAGR of 3.8% during 2021-2029.
This report focuses on Drugs for Schistosomiasis volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Drugs for Schistosomiasis market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Drugs for Schistosomiasis Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2029. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Praziquantel
Oxamniquine
Other
Segment by Application
S. haematobium
S. mansoni
S. japonicum
S. mekongi
S. intercalatum
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Shin Poong
Merck
Bayer
EIPICO
Chandra Bhagat Pharma
Taj Pharmaceuticals
1 Drugs for Schistosomiasis Market Overview
1.1 Product Overview and Scope of Drugs for Schistosomiasis
1.2 Drugs for Schistosomiasis Segment by Type
1.2.1 Global Drugs for Schistosomiasis Sales Growth Rate Comparison by Type (2021-2029)
1.2.2 Praziquantel
1.2.3 Oxamniquine
1.2.4 Other
1.3 Drugs for Schistosomiasis Segment by Application
1.3.1 Global Drugs for Schistosomiasis Sales Comparison by Application: (2021-2029)
1.3.2 S. haematobium
1.3.3 S. mansoni
1.3.4 S. japonicum
1.3.5 S. mekongi
1.3.6 S. intercalatum
1.4 Global Drugs for Schistosomiasis Market Size Estimates and Forecasts
1.4.1 Global Drugs for Schistosomiasis Revenue 2016-2029
1.4.2 Global Drugs for Schistosomiasis Sales 2016-2029
1.4.3 Drugs for Schistosomiasis Market Size by Region: 2016 Versus 2021 Versus 2029
2 Drugs for Schistosomiasis Market Competition by Manufacturers
2.1 Global Drugs for Schistosomiasis Sales Market Share by Manufacturers (2016-2021)
2.2 Global Drugs for Schistosomiasis Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Drugs for Schistosomiasis Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Drugs for Schistosomiasis Manufacturing Sites, Area Served, Product Type
2.5 Drugs for Schistosomiasis Market Competitive Situation and Trends
2.5.1 Drugs for Schistosomiasis Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Drugs for Schistosomiasis Players Market Share by Revenue
2.5.3 Global Drugs for Schistosomiasis Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Drugs for Schistosomiasis Retrospective Market Scenario by Region
3.1 Global Drugs for Schistosomiasis Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global Drugs for Schistosomiasis Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America Drugs for Schistosomiasis Market Facts & Figures by Country
3.3.1 North America Drugs for Schistosomiasis Sales by Country
3.3.2 North America Drugs for Schistosomiasis Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Drugs for Schistosomiasis Market Facts & Figures by Country
3.4.1 Europe Drugs for Schistosomiasis Sales by Country
3.4.2 Europe Drugs for Schistosomiasis Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Drugs for Schistosomiasis Market Facts & Figures by Region
3.5.1 Asia Pacific Drugs for Schistosomiasis Sales by Region
3.5.2 Asia Pacific Drugs for Schistosomiasis Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Drugs for Schistosomiasis Market Facts & Figures by Country
3.6.1 Latin America Drugs for Schistosomiasis Sales by Country
3.6.2 Latin America Drugs for Schistosomiasis Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Drugs for Schistosomiasis Market Facts & Figures by Country
3.7.1 Middle East and Africa Drugs for Schistosomiasis Sales by Country
3.7.2 Middle East and Africa Drugs for Schistosomiasis Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Drugs for Schistosomiasis Historic Market Analysis by Type
4.1 Global Drugs for Schistosomiasis Sales Market Share by Type (2016-2021)
4.2 Global Drugs for Schistosomiasis Revenue Market Share by Type (2016-2021)
4.3 Global Drugs for Schistosomiasis Price by Type (2016-2021)
5 Global Drugs for Schistosomiasis Historic Market Analysis by Application
5.1 Global Drugs for Schistosomiasis Sales Market Share by Application (2016-2021)
5.2 Global Drugs for Schistosomiasis Revenue Market Share by Application (2016-2021)
5.3 Global Drugs for Schistosomiasis Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Shin Poong
6.1.1 Shin Poong Corporation Information
6.1.2 Shin Poong Description and Business Overview
6.1.3 Shin Poong Drugs for Schistosomiasis Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Shin Poong Drugs for Schistosomiasis Product Portfolio
6.1.5 Shin Poong Recent Developments/Updates
6.2 Merck
6.2.1 Merck Corporation Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Drugs for Schistosomiasis Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Merck Drugs for Schistosomiasis Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 Bayer
6.3.1 Bayer Corporation Information
6.3.2 Bayer Description and Business Overview
6.3.3 Bayer Drugs for Schistosomiasis Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Bayer Drugs for Schistosomiasis Product Portfolio
6.3.5 Bayer Recent Developments/Updates
6.4 EIPICO
6.4.1 EIPICO Corporation Information
6.4.2 EIPICO Description and Business Overview
6.4.3 EIPICO Drugs for Schistosomiasis Sales, Revenue and Gross Margin (2016-2021)
6.4.4 EIPICO Drugs for Schistosomiasis Product Portfolio
6.4.5 EIPICO Recent Developments/Updates
6.5 Chandra Bhagat Pharma
6.5.1 Chandra Bhagat Pharma Corporation Information
6.5.2 Chandra Bhagat Pharma Description and Business Overview
6.5.3 Chandra Bhagat Pharma Drugs for Schistosomiasis Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Chandra Bhagat Pharma Drugs for Schistosomiasis Product Portfolio
6.5.5 Chandra Bhagat Pharma Recent Developments/Updates
6.6 Taj Pharmaceuticals
6.6.1 Taj Pharmaceuticals Corporation Information
6.6.2 Taj Pharmaceuticals Description and Business Overview
6.6.3 Taj Pharmaceuticals Drugs for Schistosomiasis Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Taj Pharmaceuticals Drugs for Schistosomiasis Product Portfolio
6.6.5 Taj Pharmaceuticals Recent Developments/Updates
7 Drugs for Schistosomiasis Manufacturing Cost Analysis
7.1 Drugs for Schistosomiasis Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Drugs for Schistosomiasis
7.4 Drugs for Schistosomiasis Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Drugs for Schistosomiasis Distributors List
8.3 Drugs for Schistosomiasis Customers
9 Drugs for Schistosomiasis Market Dynamics
9.1 Drugs for Schistosomiasis Industry Trends
9.2 Drugs for Schistosomiasis Growth Drivers
9.3 Drugs for Schistosomiasis Market Challenges
9.4 Drugs for Schistosomiasis Market Restraints
10 Global Market Forecast
10.1 Drugs for Schistosomiasis Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Drugs for Schistosomiasis by Type (2022-2029)
10.1.2 Global Forecasted Revenue of Drugs for Schistosomiasis by Type (2022-2029)
10.2 Drugs for Schistosomiasis Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Drugs for Schistosomiasis by Application (2022-2029)
10.2.2 Global Forecasted Revenue of Drugs for Schistosomiasis by Application (2022-2029)
10.3 Drugs for Schistosomiasis Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Drugs for Schistosomiasis by Region (2022-2029)
10.3.2 Global Forecasted Revenue of Drugs for Schistosomiasis by Region (2022-2029)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Drugs for Schistosomiasis Sales (M Units) Growth Rate Comparison by Type (2021-2029)
Table 2. Global Drugs for Schistosomiasis Sales (M Units) Comparison by Application (2021-2029)
Table 3. Global Drugs for Schistosomiasis Market Size by Region (US$ Million) (2016 VS 2021 VS 2029)
Table 4. Key Manufacturers Drugs for Schistosomiasis Covered in This Study
Table 5. Global Drugs for Schistosomiasis Sales (M Units) of Key Manufacturers (2016-2021)
Table 6. Global Drugs for Schistosomiasis Sales Market Share by Manufacturers (2016-2021)
Table 7. Global Drugs for Schistosomiasis Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Drugs for Schistosomiasis Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Drugs for Schistosomiasis Average Price (USD/K Units) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Drugs for Schistosomiasis Manufacturing Sites and Area Served
Table 11. Manufacturers Drugs for Schistosomiasis Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Drugs for Schistosomiasis by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Schistosomiasis as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Drugs for Schistosomiasis Sales by Region (2016-2021) & (M Units)
Table 16. Global Drugs for Schistosomiasis Sales Market Share by Region (2016-2021)
Table 17. Global Drugs for Schistosomiasis Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Drugs for Schistosomiasis Sales by Country (2016-2021) & (M Units)
Table 19. North America Drugs for Schistosomiasis Sales Market Share by Country (2016-2021)
Table 20. North America Drugs for Schistosomiasis Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Drugs for Schistosomiasis Revenue Market Share by Country (2016-2021)
Table 22. Europe Drugs for Schistosomiasis Sales by Country (2016-2021) & (M Units)
Table 23. Europe Drugs for Schistosomiasis Sales Market Share by Country (2016-2021)
Table 24. Europe Drugs for Schistosomiasis Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Drugs for Schistosomiasis Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Drugs for Schistosomiasis Sales by Region (2016-2021) & (M Units)
Table 27. Asia Pacific Drugs for Schistosomiasis Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Drugs for Schistosomiasis Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Drugs for Schistosomiasis Revenue Market Share by Region (2016-2021)
Table 30. Latin America Drugs for Schistosomiasis Sales by Country (2016-2021) & (M Units)
Table 31. Latin America Drugs for Schistosomiasis Sales Market Share by Country (2016-2021)
Table 32. Latin America Drugs for Schistosomiasis Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Drugs for Schistosomiasis Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Drugs for Schistosomiasis Sales by Country (2016-2021) & (M Units)
Table 35. Middle East and Africa Drugs for Schistosomiasis Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Drugs for Schistosomiasis Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Drugs for Schistosomiasis Revenue Market Share by Country (2016-2021)
Table 38. Global Drugs for Schistosomiasis Sales (M Units) by Type (2016-2021)
Table 39. Global Drugs for Schistosomiasis Sales Market Share by Type (2016-2021)
Table 40. Global Drugs for Schistosomiasis Revenue (Million US$) by Type (2016-2021)
Table 41. Global Drugs for Schistosomiasis Revenue Share by Type (2016-2021)
Table 42. Global Drugs for Schistosomiasis Price (USD/K Units) by Type (2016-2021)
Table 43. Global Drugs for Schistosomiasis Sales (M Units) by Application (2016-2021)
Table 44. Global Drugs for Schistosomiasis Sales Market Share by Application (2016-2021)
Table 45. Global Drugs for Schistosomiasis Revenue (Million US$) by Application (2016-2021)
Table 46. Global Drugs for Schistosomiasis Revenue Share by Application (2016-2021)
Table 47. Global Drugs for Schistosomiasis Price (USD/K Units) by Application (2016-2021)
Table 48. Shin Poong Corporation Information
Table 49. Shin Poong Description and Business Overview
Table 50. Shin Poong Drugs for Schistosomiasis Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 51. Shin Poong Drugs for Schistosomiasis Product
Table 52. Shin Poong Recent Developments/Updates
Table 53. Merck Corporation Information
Table 54. Merck Description and Business Overview
Table 55. Merck Drugs for Schistosomiasis Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 56. Merck Drugs for Schistosomiasis Product
Table 57. Merck Recent Developments/Updates
Table 58. Bayer Corporation Information
Table 59. Bayer Description and Business Overview
Table 60. Bayer Drugs for Schistosomiasis Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 61. Bayer Drugs for Schistosomiasis Product
Table 62. Bayer Recent Developments/Updates
Table 63. EIPICO Corporation Information
Table 64. EIPICO Description and Business Overview
Table 65. EIPICO Drugs for Schistosomiasis Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 66. EIPICO Drugs for Schistosomiasis Product
Table 67. EIPICO Recent Developments/Updates
Table 68. Chandra Bhagat Pharma Corporation Information
Table 69. Chandra Bhagat Pharma Description and Business Overview
Table 70. Chandra Bhagat Pharma Drugs for Schistosomiasis Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 71. Chandra Bhagat Pharma Drugs for Schistosomiasis Product
Table 72. Chandra Bhagat Pharma Recent Developments/Updates
Table 73. Taj Pharmaceuticals Corporation Information
Table 74. Taj Pharmaceuticals Description and Business Overview
Table 75. Taj Pharmaceuticals Drugs for Schistosomiasis Sales (M Units), Revenue (Million US$), Price (USD/K Units) and Gross Margin (2016-2021)
Table 76. Taj Pharmaceuticals Drugs for Schistosomiasis Product
Table 77. Taj Pharmaceuticals Recent Developments/Updates
Table 78. Production Base and Market Concentration Rate of Raw Material
Table 79. Key Suppliers of Raw Materials
Table 80. Drugs for Schistosomiasis Distributors List
Table 81. Drugs for Schistosomiasis Customers List
Table 82. Drugs for Schistosomiasis Market Trends
Table 83. Drugs for Schistosomiasis Growth Drivers
Table 84. Drugs for Schistosomiasis Market Challenges
Table 85. Drugs for Schistosomiasis Market Restraints
Table 86. Global Drugs for Schistosomiasis Sales Forecast by Type (2022-2029) & (M Units)
Table 87. Global Drugs for Schistosomiasis Sales Market Share Forecast by Type (2022-2029)
Table 88. Global Drugs for Schistosomiasis Revenue Forecast by Type (2022-2029) & (US$ Million)
Table 89. Global Drugs for Schistosomiasis Revenue Market Share Forecast by Type (2022-2029)
Table 90. Global Drugs for Schistosomiasis Sales Forecast by Application (2022-2029) & (M Units)
Table 91. Global Drugs for Schistosomiasis Sales Market Share Forecast by Application (2022-2029)
Table 92. Global Drugs for Schistosomiasis Revenue Forecast by Application (2022-2029) & (US$ Million)
Table 93. Global Drugs for Schistosomiasis Revenue Market Share Forecast by Application (2022-2029)
Table 94. Global Drugs for Schistosomiasis Sales Forecast by Region (2022-2029) & (M Units)
Table 95. Global Drugs for Schistosomiasis Sales Market Share Forecast by Region (2022-2029)
Table 96. Global Drugs for Schistosomiasis Revenue Forecast by Region (2022-2029) & (US$ Million)
Table 97. Global Drugs for Schistosomiasis Revenue Market Share Forecast by Region (2022-2029)
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Drugs for Schistosomiasis
Figure 2. Global Drugs for Schistosomiasis Market Share by Type in 2020 & 2029
Figure 3. Praziquantel Product Picture
Figure 4. Oxamniquine Product Picture
Figure 5. Other Product Picture
Figure 6. Global Drugs for Schistosomiasis Market Share by Application in 2020 & 2029
Figure 7. S. haematobium
Figure 8. S. mansoni
Figure 9. S. japonicum
Figure 10. S. mekongi
Figure 11. S. intercalatum
Figure 12. Global Drugs for Schistosomiasis Revenue, (US$ Million), 2016 VS 2021 VS 2029
Figure 13. Global Drugs for Schistosomiasis Market Size 2016-2029 (US$ Million)
Figure 14. Global Drugs for Schistosomiasis Sales 2016-2029 (M Units)
Figure 15. Global Drugs for Schistosomiasis Market Size Market Share by Region: 2016 VS 20210 VS 2029
Figure 16. Drugs for Schistosomiasis Sales Share by Manufacturers in 2020
Figure 17. Global Drugs for Schistosomiasis Revenue Share by Manufacturers in 2020
Figure 18. The Global 5 and 10 Largest Drugs for Schistosomiasis Players: Market Share by Revenue in 2020
Figure 19. Drugs for Schistosomiasis Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 20. Global Drugs for Schistosomiasis Sales Market Share by Region (2016-2021)
Figure 21. Global Drugs for Schistosomiasis Sales Market Share by Region in 2020
Figure 22. Global Drugs for Schistosomiasis Revenue Market Share by Region (2016-2021)
Figure 23. Global Drugs for Schistosomiasis Revenue Market Share by Region in 2020
Figure 24. U.S. Drugs for Schistosomiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. Canada Drugs for Schistosomiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. Germany Drugs for Schistosomiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. France Drugs for Schistosomiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. U.K. Drugs for Schistosomiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Italy Drugs for Schistosomiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. Russia Drugs for Schistosomiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. China Drugs for Schistosomiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. Japan Drugs for Schistosomiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. South Korea Drugs for Schistosomiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. India Drugs for Schistosomiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Australia Drugs for Schistosomiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Taiwan Drugs for Schistosomiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Indonesia Drugs for Schistosomiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Thailand Drugs for Schistosomiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Malaysia Drugs for Schistosomiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Philippines Drugs for Schistosomiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Vietnam Drugs for Schistosomiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Mexico Drugs for Schistosomiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Brazil Drugs for Schistosomiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Argentina Drugs for Schistosomiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Turkey Drugs for Schistosomiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Saudi Arabia Drugs for Schistosomiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 47. U.A.E Drugs for Schistosomiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 48. Sales Market Share of Drugs for Schistosomiasis by Type (2016-2021)
Figure 49. Sales Market Share of Drugs for Schistosomiasis by Application (2016-2021)
Figure 50. Sales Market Share of Drugs for Schistosomiasis by Application in 2020
Figure 51. Revenue Share of Drugs for Schistosomiasis by Application (2016-2021)
Figure 52. Revenue Share of Drugs for Schistosomiasis by Application in 2020
Figure 53. Manufacturing Cost Structure of Drugs for Schistosomiasis
Figure 54. Manufacturing Process Analysis of Drugs for Schistosomiasis
Figure 55. Drugs for Schistosomiasis Industrial Chain Analysis
Figure 56. Channels of Distribution
Figure 57. Distributors Profiles
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
The research methodology employed by VICResearch has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of VICResearch. VICResearch’s methodology can be divided into five stages:
Stage 1: Secondary research
The research team first works with magazines, industry trade group, and administration that operate in the research field. The information provided by our in-house documentation service helps us carrying out further research. Our team which has the experience as well as the knowledge efficiently extracts the accurate information from existing source.
Stage 2: Primary research: interviews with trade sources
After the first stage, the research team conducts large number of face-to-face or telephone interviews with the representative companies operating in the research field. The analysts attempt to obtain a chance to talk with leading players in the field as well as with small companies. The upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers are all included in the interviews. The data gathered during the interview is then carefully checked and compared with the secondary research.
Stage 3: Analysis of the gathered data
The analysis team checks and synthesizes the data gathered during the first two stages. To validate the data, a second series of interviews can be conducted.
Stage 4: Quantitative data
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by VICResearch. The data is based on the estimates obtained during stage 3.
The research team also provides appreciation and analysis of the market and the quantitative data contained in the reports. The data is consequently unique to VICResearch.
Stage 5: Quality control
Before publishing, every report goes under a rigorous checking and editing process, which is done by experience management team to ensure the reliability of the published data. Each analyst in the research team receives support and on-going training which is part of the VICResearch’s internal quality process.
Consulting report: +86-15323335301 020-31521856
